Phase 3 Recruiting Network
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care …
Sponsor: Children's Oncology Group
NCT ID: NCT05602194
Sites in Tennessee: - East Tennessee Childrens Hospital — Knoxville, Tennessee
- The Children's Hospital at TriStar Centennial — Nashville, Tennessee
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 3 Recruiting Industry
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AM…
Sponsor: Daiichi Sankyo
NCT ID: NCT06578247
Sites in Tennessee: - Tristar Bone Marrow Transplant — Nashville, Tennessee
Phase 3 Recruiting Academic/Other
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st r…
Sponsor: PedAL BCU, LLC
NCT ID: NCT05183035
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
- Monroe Carell Jr. Children's Hospital at Vanderbilt — Nashville, Tennessee
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in Tennessee: - Tennessee Oncology-Chattanooga ( Site 0045) — Chattanooga, Tennessee
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0031) — Nashville, Tennessee
Phase 3 Recruiting Industry
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT07007312
Sites in Tennessee: - Baptist Clinical Research Institute — Memphis, Tennessee
- Tennessee Oncology — Nashville, Tennessee
- TriStar Centennial Medical Center — Nashville, Tennessee
Phase 2, Phase 3 Recruiting Industry
Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at es…
Sponsor: Taiho Oncology, Inc.
NCT ID: NCT04256317
Sites in Tennessee: - Vanderbilt University Medical Center — Nashville, Tennessee
Phase 3 Recruiting Industry
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Sites in Tennessee: - Sarah Cannon Research Institute SCRI — Nashville, Tennessee
Phase 2 Recruiting NIH
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myelo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564390
Sites in Tennessee: - Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
- University of Tennessee - Knoxville — Knoxville, Tennessee
- Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML)…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554406
Sites in Tennessee: - Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
- University of Tennessee - Knoxville — Knoxville, Tennessee
- Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Tennessee: - East Tennessee Childrens Hospital — Knoxville, Tennessee
- The Children's Hospital at TriStar Centennial — Nashville, Tennessee
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in Tennessee: - Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
- Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
Phase 1, Phase 2 Recruiting Academic/Other
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…
Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in Tennessee: - East Tennessee Childrens Hospital — Knoxville, Tennessee
- Saint Jude Children's Research Hospital — Memphis, Tennessee
- The Children's Hospital at TriStar Centennial — Nashville, Tennessee
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Tennessee: - East Tennessee Childrens Hospital — Knoxville, Tennessee
- Saint Jude Children's Research Hospital — Memphis, Tennessee
- The Children's Hospital at TriStar Centennial — Nashville, Tennessee
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017…
Sponsor: Juno Therapeutics, a Subsidiary of Celgene
NCT ID: NCT03331198
Sites in Tennessee: - Sarah Cannon Research Institute - Tennessee Oncology — Nashville, Tennessee
Phase 2 Recruiting Industry
This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp (9 and 12 micrograms/kilogram/day \[μg/kg/day\]), used in combination with venetoclax and azacitidine, to determine the dose for Part …
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06456463
Sites in Tennessee: - Sarah Cannon, the Cancer Institute of HCA Healthcare — Nashville, Tennessee
- Tennessee Oncology — Nashville, Tennessee
Phase 2 Recruiting Industry
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of tre…
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT06588478
Sites in Tennessee: - The West Clinic, PLLC dba West Cancer Center — Germantown, Tennessee
Phase 1, Phase 2 Recruiting Academic/Other
This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-…
Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
NCT ID: NCT05849662
Sites in Tennessee: - St. Jude Children's Research Hospital Memphis — Memphis, Tennessee
Phase 1, Phase 2 Recruiting Industry
The goal of the study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of TERN-701, a highly selective allosteric inhibitor of BCR-ABL1, in participants with previously treated chronic phase - chroni…
Sponsor: Terns, Inc.
NCT ID: NCT06163430
Sites in Tennessee: - Tristar BMT — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
Sponsor: Vironexis Biotherapeutics Inc.
NCT ID: NCT06533579
Sites in Tennessee: - TriStar BMT — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute and chronic leukemias, myelodysplastic syndrome, and certain lymphomas. …
Sponsor: Ossium Health, Inc.
NCT ID: NCT05589896
Sites in Tennessee: - TriStar Bone Marrow Transplant — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
This study is testing Allo-QuadCAR01-T, a new off-the-shelf CAR-T therapy for people with hard-to-treat B-cell cancers. Unlike current CAR-T treatments that use a patient's own cells, this therapy uses donor cells that are ready to use, wh…
Sponsor: AvenCell Therapeutics, Inc.
NCT ID: NCT07284433
Sites in Tennessee: - Sarah Cannon Research Institute — Nashville, Tennessee
Phase 2 Recruiting Academic/Other
This is a clinical trial testing whether the addition of one of two chemotherapy agents, dasatinib or venetoclax, can improve outcomes for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma or m…
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT06390319
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Phase 1, Phase 2 Recruiting Academic/Other
This is a phase I/II clinical trial assessing the tolerability and efficacy of CM4620 in children and young adults with acute pancreatitis caused by asparaginase. The tolerability of CM4620 when given to patients receiving frontline chemot…
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT04195347
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Phase 1, Phase 2 Recruiting Industry
The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.
Sponsor: Amgen
NCT ID: NCT07134088
Sites in Tennessee: - St Jude Childrens Research Hospital — Memphis, Tennessee
Phase 2 Recruiting Academic/Other
CAR19PK is a research study evaluating the use of lymphodepleting chemotherapy and chimeric antigen receptor (CAR) T cell therapy, a type of cellular therapy, for the treatment of refractory and/or relapsed leukemia. For this type of thera…
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT06847269
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee